The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma

References

• Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Scoazec JY, Couvelard A, Réseau T. [Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future]. Ann Pathol. 2017;37:444–456.
   PubMed Web of Science ®Google Scholar
• Ito Y, Nikiforov YE, Schlumberger M, et al. Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol. 2013;9:178–184.
   PubMed Web of Science ®Google Scholar
• Seib CD, Sosa JA. Evolving Understanding of the Epidemiology of Thyroid Cancer. Endocrinol Metab Clin North Am. 2019;48:23–35.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Scharpf J. Achieving Active Surveillance for Thyroid Cancer-Not a Euphemism for Watching a Ticking Time Bomb. JAMA Otolaryngol Head Neck Surg. 2017;143:1021–1022.
   PubMed Web of Science ®Google Scholar
• Vaccarella S, et al. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med. 2016;375:614–617. doi:10.1056/NEJMp1604412.
   PubMed Web of Science ®Google Scholar
• Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. doi:10.1089/thy.2015.0020.
   PubMed Web of Science ®Google Scholar
• Raue F, Frank-Raue K. Thyroid Cancer: risk-Stratified Management and Individualized Therapy. Clin Cancer Res. 2016;22:5012–5021.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(1423–1437). DOI:10.1038/nm.3394
   Google Scholar
• Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–458.
   PubMed Web of Science ®Google Scholar
• Fan T, et al. Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma. Aging (Albany NY). 2020;12. DOI:10.18632/aging.202269.
   Google Scholar
• Privat-Maldonado A, Bengtson C, Razzokov J, et al. Modifying the Tumour Microenvironment: challenges and Future Perspectives for Anticancer Plasma Treatments. Cancers (Basel). 2019;11. DOI:10.3390/cancers11121920.
   Web of Science ®Google Scholar
• Şenbabaoğlu Y, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17(231). DOI:10.1186/s13059-016-1092-z
   PubMedGoogle Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–322.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: mechanisms of progression and immunotherapy. World J Gastroenterol. 2019;25:3151–3167.
   PubMed Web of Science ®Google Scholar
• Bi KW, Wei XG, Qin XX, et al. BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: a Study Based on TCGA Data Mining. Front Oncol. 2020;10(424). DOI:10.3389/fonc.2020.00424
   Google Scholar
• Xu L, et al. The role of CCR2 in prognosis of patients with endometrial cancer and tumor microenvironment remodeling. Bioengineered. 2021;12:3467–3484. doi:10.1080/21655979.2021.1947631.
   PubMed Web of Science ®Google Scholar
• Wang T, Chen B, Meng T, et al. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma. Bioengineered. 2021;12:1555–1575.
   PubMed Web of Science ®Google Scholar
• Jolly LA, et al. Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss. Cancer Res. 2016;76:1804–1813. doi:10.1158/0008-5472.CAN-15-2351.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4: 2612. DOI:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Chakraborty H, Hossain A. R package to estimate intracluster correlation coefficient with confidence interval for binary data. Comput Methods Programs Biomed. 2018;155(85–92). DOI:10.1016/j.cmpb.2017.10.023
   PubMedGoogle Scholar
• Yang SYC, et al. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Med. 2018;10(81). DOI:10.1186/s13073-018-0590-x
   Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30.
   PubMed Web of Science ®Google Scholar
• Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–2504. doi:10.1101/gr.1239303.
   PubMed Web of Science ®Google Scholar
• Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Calo PG, et al. Intraoperative neuromonitoring in thyroid surgery: is the two-staged thyroidectomy justified? Int J Surg. 2017;41(Suppl 1):S13–S20. doi:10.1016/j.ijsu.2017.02.001.
   PubMedGoogle Scholar
• Conzo G, et al. The current status of lymph node dissection in the treatment of papillary thyroid cancer. A literature review. Clin Ter. 2013;164:e343–346. doi:10.7417/CT.2013.1599.
   PubMed Web of Science ®Google Scholar
• Pezzolla A, et al. [Incidental thyroid carcinoma: a multicentric experience]. Recenti Prog Med. 2010;101:194–198.
   PubMedGoogle Scholar
• Zhang S, et al. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas. BMC Cancer. 2020;20:127. DOI:10.1186/s12885-020-6545-9
   Google Scholar
• van Den Meiracker AH, Danser AH, Sleijfer S, et al. Re: hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:1557. author reply 1558
   PubMedGoogle Scholar
• Cao J, et al. Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: based on TCGA Database and Bioinformatics. Front Oncol. 2019;9:1533. DOI:10.3389/fonc.2019.01533
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Wang J, et al. CD52 Is a Prognostic Biomarker and Associated With Tumor Microenvironment in Breast Cancer. Front Genet. 2020;11: 578002. DOI:10.3389/fgene.2020.578002
   PubMed Web of Science ®Google Scholar
• Porcelli T, Sessa F, Luongo C, et al. Local ablative therapy of oligoprogressive TKI-treated thyroid cancer. J Endocrinol Invest. 2019;42(871–879). DOI:10.1007/s40618-019-1001-x
   PubMedGoogle Scholar
• Xu ZY, et al. Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma. PeerJ. 2020;8:e9530. DOI:10.7717/peerj.9530
   Google Scholar
• Revel M, Daugan MV, Sautes-Fridman C, et al. Complement System: promoter or Suppressor of Cancer Progression? Antibodies (Basel). 2020;9. DOI:10.3390/antib9040057.
   PubMedGoogle Scholar
• Liu J, et al. ATP2C2 Has Potential to Define Tumor Microenvironment in Breast Cancer. Front Immunol. 2021;12:657950. DOI:10.3389/fimmu.2021.657950
   Google Scholar
• Riihila P, et al. Complement Component C3 and Complement Factor B Promote Growth of Cutaneous Squamous Cell Carcinoma. Am J Pathol. 2017;187:1186–1197. doi:10.1016/j.ajpath.2017.01.006.
   PubMed Web of Science ®Google Scholar
• Kim SH, et al. Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: a pilot study. Cancer Biomark. 2019;24:335–342. DOI:10.3233/CBM-181847
   Google Scholar
• Cayrol F, Sterle HA, Díaz Flaqué MC, et al. Non-genomic Actions of Thyroid Hormones Regulate the Growth and Angiogenesis of T Cell Lymphomas. Front Endocrinol (Lausanne). 2019;10(63). DOI:10.3389/fendo.2019.00063
   PubMedGoogle Scholar
• Ferrari SM, et al. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int J Mol Sci. 2019;20. DOI:10.3390/ijms20184413.
   Web of Science ®Google Scholar
• Xie Z, et al. Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods. BMC Cancer. 2020;20:1143. DOI:10.1186/s12885-020-07620-8
   Google Scholar
• Lin X, et al. ADORA1 is a diagnostic-related biomarker and correlated with immune infiltrates in papillary thyroid carcinoma. J Cancer. 2021;12:3997–4010. DOI:10.7150/jca.50743
   Google Scholar